If 2020 was the year that ICARS moved from concept to reality, 2021 was the year that ICARS sprang into action. Despite continued challenges posed by COVID-19, ICARS made great strides in 2021 including establishing itself as a self-governing institution, building a diverse portfolio of projects across Latin America, Asia, and Africa, and advocating for intervention and implementation research to tackle antimicrobial resistance (AMR) at multiple high-level events.
We enter the new year with great momentum. In the first half of 2022, we are excited to finalise, with our Board’s support and advice, our four- year strategy with a clear roadmap for delivering our ambitious agenda by 2026. In this, our second annual report, we are proud to present our key achievements over the past year and the contribution of ICARS to global efforts to reduce drug-resistant infections.
